Loading…
Loading…
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Stifel Financial Corporation (NYSE: SF) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 10,000 shares of the financial services provider's stock, valued at approximately $698,000. A number of
Amundi reduced its holdings in shares of Stifel Financial Corporation (NYSE: SF) by 68.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 153,885 shares of the financial services provider's stock after selling 337,532 shares during the period. Amundi
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the third quarter of 2026.
MISSION Group (LSE:TMG) drew a bullish call from Stifel, which argued the marketing group's valuation overlooks a profit recovery driven by cost cuts and agency consolidation. The shares traded at 23.85p, up 4%, while the broker initiated coverage with a 'buy' rating and a 57p target, more than double the share price.
ST. LOUIS & LONDON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the appointments of Conor Daly and Jim Franz as Co-Heads of Leveraged Finance Sales in Europe, further strengthening the firm's global Fixed Income platform.
Canada Pension Plan Investment Board purchased a new position in Stifel Financial Corporation (NYSE: SF) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 93,950 shares of the financial services provider's stock, valued at approximately $6,555,000. Canada Pension Plan Investment Board
ST. LOUIS, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for July 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed.
Stifel has reiterated its 'buy' rating on Faron Pharmaceuticals Limited (AIM:FARN), the Finnish biotech, maintaining a price target of €2.50 after the company's interims, which showed the company well-funded to push on with value-accretive work in the clinic. The stock closed at €0.48 on 25 August, implying upside of 418.1% to the target price.
SEC filings for SF aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.